TISSUSE GMBH
History
| Year | Detail |
|---|---|
| 2010 | TissUse GmbH is a spin-off company from the TU Berlin, founded in 2010 by Dr. Uwe Marx. It has developed a unique chip-based tissue culture platform that enables the testing of drugs or chemicals using a series of miniaturized and interconnected human organs (organoids) that simulate the biology of the human organism. |
| 2017 | ProBioGen AG and TissUse GmbH signed a license and cooperation agreement to integrate ProBioGen’s Human Artificial Lymph Node Model into TissUse's Multi-Organ-Chip technology. |
| 2018 | The company collaborated with AstraZeneca to establish relevant Microphysiological System (MPS) models based on TissUse’s Multi-Organ-Chip technology. |
| 2018 | The company collaborated with Bayer to develop a highly innovative liver-endocrine tissue assay using TissUse’s Multi-Organ-Chip (MOC) technology. |
| 2021 | Philip Morris International and TissUse collaborated to utilize PMI’s InHALES technology in combination with TissUse’s proprietary Multi-Organ-Chip (MOC) platform to enable inhalation exposure of functional human tissues in homeostasis at minute scale in vitro. |
| 2022 | The company received funding from the Bill & Melinda Gates Foundation for a three-year project to develop a vascularized microphysiological system interconnecting human lung, liver, and lymph node organoids capable of screening Tuberculosis vaccine candidates and treatment modalities. |
BCC Research Beacon 